These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35136963)

  • 41. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.
    Blair AB; Rosati LM; Rezaee N; Gemenetzis G; Zheng L; Hruban RH; Cameron JL; Weiss MJ; Wolfgang CL; Herman JM; He J
    Surgery; 2018 May; 163(5):1090-1096. PubMed ID: 29395234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
    Satoi S; Yanagimoto H; Toyokawa H; Takahashi K; Matsui Y; Kitade H; Mergental H; Tanigawa N; Takai S; Kwon AH
    Pancreas; 2009 Apr; 38(3):282-8. PubMed ID: 19142173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
    Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):109-120. PubMed ID: 33825991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.
    Sho M; Akahori T; Tanaka T; Kinoshita S; Tamamoto T; Nomi T; Yamato I; Hokuto D; Yasuda S; Kawaguchi C; Nishiofuku H; Marugami N; Enomonoto Y; Kasai T; Hasegawa M; Kichikawa K; Nakajima Y
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):197-205. PubMed ID: 22766692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma.
    Einama T; Kamachi H; Tsuruga Y; Sakata T; Shibuya K; Sakamoto Y; Shimada S; Wakayama K; Orimo T; Yokoo H; Kamiyama T; Katoh N; Uchinami Y; Mitsuhashi T; Taketomi A
    Medicine (Baltimore); 2018 Aug; 97(31):e11309. PubMed ID: 30075497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
    Itchins M; Arena J; Nahm CB; Rabindran J; Kim S; Gibbs E; Bergamin S; Chua TC; Gill AJ; Maher R; Diakos C; Wong M; Mittal A; Hruby G; Kneebone A; Pavlakis N; Samra J; Clarke S
    Eur J Surg Oncol; 2017 Sep; 43(9):1711-1717. PubMed ID: 28688722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
    Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
    Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable Pancreatic Cancer: A Retrospective Study.
    Suto H; Fuke T; Matsukawa H; Ando Y; Oshima M; Nagao M; Takahashi S; Shibata T; Yamana H; Kamada H; Kobara H; Okuyama H; Kumamoto K; Okano K
    J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592055
    [No Abstract]   [Full Text] [Related]  

  • 50. Role of Short-Term Neoadjuvant Chemoradiotherapy for Potentially Resectable Pancreatic Cancer.
    Okano K; Suto H; Oshima M; Ando Y; Matsukawa H; Kamada H; Kobara H; Masaki T; Suzuki Y
    Am Surg; 2022 Jun; 88(6):1298-1303. PubMed ID: 33629878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
    Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
    World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective.
    Kurata Y; Shiraki T; Ichinose M; Kubota K; Imai Y
    World J Surg Oncol; 2021 Mar; 19(1):85. PubMed ID: 33752677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
    Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
    J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
    Amin S; Baine M; Meza J; Lin C
    BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Total neoadjuvant therapy is associated with improved overall survival and pathologic response in pancreatic adenocarcinoma.
    Villano AM; O'Halloran E; Goel N; Ruth K; Barrak D; Lefton M; Reddy SS
    J Surg Oncol; 2022 Sep; 126(3):502-512. PubMed ID: 35476892
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma.
    Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
    Anticancer Res; 2021 Mar; 41(3):1629-1639. PubMed ID: 33788759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by curative pancreatic resection: A retrospective study using prospectively collected data.
    Suto H; Matsukawa H; Ando Y; Oshima M; Fuke T; Nagao M; Yamana H; Kamada H; Kumamoto K; Okano K
    J Hepatobiliary Pancreat Sci; 2024 Mar; ():. PubMed ID: 38462668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
    Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
    Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.